Heart failure & cardiomyopathiesCohort study
Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality
- retrospective cohort study
- multivariable Cox models
Authors' conclusion
Across 2 real-world populations, diagnostic delay in ATTR-CM is a clinically meaningful marker of disease progression, with longer delays associated with increased HFH and mortality.
Study context
- Population
- Patients with heart failure (HF) diagnosed with ATTR-CM between 2016 and 2022, Medicare fee-for-service and Veterans Health Administration (VHA) dataPatients with HF and ATTR-CM in two cohorts · Medicare beneficiaries 7,770 · Veterans (VHA) 2,557
- Participants
- 7,770 vs 2,557
- Exposure
- Time-to-diagnosis, per 1-year delay, and death or HF hospitalization (HFH)
- Medicaren = 7,770
- VHAn = 2,557
- Outcome
- Death or HFH
Main finding
As reported in the abstract
Hazard ratio, per 1-year delay (95% CI)
Medicare
1.07(1.06–1.08)
VHA
1.07(1.05–1.09)
Per 1-year delay, as printed
- Each 1-year delay associated with increased risk of the primary outcome
- 7%
Observational data: associations, not effects.
Further findings
Age at diagnosis
Women
Time-to-diagnosis
Original publication
Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality. JACC Adv. Published 22 July 2026. doi:10.1016/j.jacadv.2026.103019
Summarised from the published abstract; every number is checked against it